Elsevier purchases oncology portfolio
“The CIG titles are attractive because they provide high-quality peer-reviewed content—which Elsevier will seek to further improve in partnership with the editorial teams—in this dynamic area of research and clinical practice,” said Tom Reller, Elsevier's VP, global corporate relations, in an email. “Oncology is an important growth area for Elsevier, with increasing disease incidence, new therapeutic options for patients, and increasing numbers of papers published each year,” he said.
The titles, which include Clinical Breast Cancer, Clinical Lung Cancer, Clinical Lymphoma Myeloma & Leukemia, Clinical Colorectal Cancer, Clinical Ovarian Cancer and Clinical Genitourinary Cancer, will be available online and in print, with advertising opportunities available in both formats, Reller said.
Glen Campbell, EVP, global medical research, Elsevier, said in a statement that “Authors will benefit from the upcoming release of enhanced online manuscript submission and review systems for the journals, as well as the range of author support tools provided by Elsevier.”